Literature DB >> 28759937

Prevalence, Clinical Features, and Natural History of Incidental Clinically Non-Functioning Pituitary Adenomas.

Pedro Iglesias1, Karina Arcano1, Vanessa Triviño2, Paula García-Sancho3, Juan José Díez1,4, Carles Villabona3, Fernando Cordido2.   

Abstract

The objective of the study was to assess the prevalence and clinical features of incidentally discovered clinically non-functioning pituitary adenoma (CNFPA) and to analyze its natural history. A multicenter retrospective study in patients diagnosed with incidental CNFPA periodically followed-up in 3 specialized neuroendocrinology units from 1992 to 2015 was performed. Out of a total of 189 CNFPA patients, 57 cases (30.1%; 29 women; age at diagnosis 55.8±16.7 years) were incidental. Most patients (n=55, 96.5%) were diagnosed by magnetic resonance imaging (MRI). A sum of 71.9% (n=41) were macroadenomas; 2 of them (3.5%) were giant adenomas (≥4 cm). Patients with macroadenomas were older than those with microadenomas (59.5±16.7 vs. 46.4±18.1 years, p=0.007). Macroadenomas were more common in men (85.7% vs. 58.6%, p=0.023). Twenty-eight patients (49.1%) showed suprasellar extension; of these, 19 were accompanied by chiasmatic compression. Hypopituitarism was present in 14 (24.6%) patients; which was partial in 13 patients (22.8%) and complete in one patient (1.8%). The gonadal axis was the most frequently affected (n=13, 22.8%). Twenty four patients (42.1%) underwent surgery. Of the non-operated patients, 26 patients could be evaluated morphologically after a median follow-up of 15.5 months (interquartile range, 5.7-32.7 months). No significant changes were found in the maximum tumor diameter at the end of follow-up (1.2±0.6 vs 1.2±0.7 cm). The majority of CNFPAs evaluated (n=23, 88.5%) did not show any changes in size. In 2 cases (7.7%) tumor size decreased, and in one patient (3.8%) increased. In our series of CNFPA patients, approximately one-third were incidental. These tumors were diagnosed by MRI preferably from the 5th decade of life without sex predilection. Most of them were macroadenomas, more commonly diagnosed in men and at an older age, compared to microadenomas. The suprasellar extension with chiasmatic compression and hypopituitarism were frequent at diagnosis. Most of the non-operated incidental CNFPAs remain with stable tumor size over time, growth being an unusual event. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2017        PMID: 28759937     DOI: 10.1055/s-0043-115645

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  10 in total

Review 1.  Guidelines in the management of CNS tumors.

Authors:  Navid Redjal; Andrew S Venteicher; Danielle Dang; Andrew Sloan; Remi A Kessler; Rebecca R Baron; Constantinos G Hadjipanayis; Clark C Chen; Mateo Ziu; Jeffrey J Olson; Brian V Nahed
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

Review 2.  Management of nonfunctioning pituitary adenomas (NFAs): observation.

Authors:  Wenyu Huang; Mark E Molitch
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

3.  Is there any gender difference in epidemiology, clinical presentation and co-morbidities of non-functioning pituitary adenomas? A prospective survey of a National Referral Center and review of the literature.

Authors:  C Di Somma; E Scarano; G de Alteriis; L Barrea; E Riccio; R Arianna; S Savastano; A Colao
Journal:  J Endocrinol Invest       Date:  2020-09-07       Impact factor: 4.256

Review 4.  Management of NFAs: medical treatment.

Authors:  Naomi Even-Zohar; Yona Greenman
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

5.  Early hormonal recovery following endoscopic transsphenoidal surgery for silent non-functioning pituitary adenomas with hormone dysfunction.

Authors:  Min Ho Lee; Kyu Yeon Hur; Sang Duk Hong; Ho Jun Seol; Jung Won Choi; Jung- Il Lee; Do-Hyun Nam; Doo-Sik Kong
Journal:  J Neurooncol       Date:  2021-05-17       Impact factor: 4.130

6.  Epidemiology of common and uncommon adult pituitary tumors in the U.S. according to the 2017 World Health Organization classification.

Authors:  Luz E Castellanos; Catherine Gutierrez; Timothy Smith; Edward R Laws; J Bryan Iorgulescu
Journal:  Pituitary       Date:  2021-09-27       Impact factor: 4.107

7.  Factors Associated with and Temporal Trends in the Use of Radiation Therapy for the Treatment of Pituitary Adenoma in the National Cancer Database.

Authors:  Ramie Fathy; Edward Kuan; John Y K Lee; M Sean Grady; Michelle Alonso-Basanta; James N Palmer; Nithin D Adappa; Bert W O'Malley; Jason Brant
Journal:  J Neurol Surg B Skull Base       Date:  2019-10-04

8.  18 beta-glycyrrhetinic acid ameliorates the cognitive functions and decreases the recurrence rate of pituitary adenomas patients.

Authors:  Xianxiang Wang; Yiquan Zhang; Jin Xiao; Ke Zhang; Qingxin Li; Hongwei Chen; Fei Liu
Journal:  EXCLI J       Date:  2018-07-27       Impact factor: 4.068

Review 9.  An Overview of Pituitary Incidentalomas: Diagnosis, Clinical Features, and Management.

Authors:  Shigeyuki Tahara; Yujiro Hattori; Koji Suzuki; Eitaro Ishisaka; Shinichiro Teramoto; Akio Morita
Journal:  Cancers (Basel)       Date:  2022-09-03       Impact factor: 6.575

10.  Do TRIB1 and IL-9 Gene Polymorphisms Impact the Development and Manifestation of Pituitary Adenoma?

Authors:  Tomas Mickevicius; Alvita Vilkeviciute; Brigita Glebauskiene; Loresa Kriauciuniene; Rasa Liutkeviciene
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.